SCHEMBL17135764

SCHEMBL17135764

Nc1nc(-c2ccc(-c3ccccc3)cc2)c(Cl)cc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE7A Q13946 1/20 0.45
▸ DHFR P00374 1/20 0.44
▸ KMT2A Q03164 6/20 0.43
▸ MEN1 O00255 5/20 0.43
▸ PIN1 Q13526 1/20 0.43
▸ MAPT P10636 6/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ CRHBP P24387 1/20 0.43
▸ CRHR2 Q13324 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ NCOA1 Q15788 1/20 0.41
▸ NCOA3 Q9Y6Q9 1/20 0.41
▸ PSMD14 O00487 1/20 0.41
▸ PRKACA P17612 1/20 0.41
▸ CASP6 P55212 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17135782 0.83 KMT2A (0.46) PDE7ADHFRKMT2AMEN1PIN1
SCHEMBL15721857 0.77 MAPT (0.53) KMT2AMEN1MAPTALDH1A1SMN1; SMN2
SCHEMBL15602177 0.77 KDM4E (0.48) DHFRALDH1A1SMN1; SMN2ADORA2AADORA1
SCHEMBL4228185 0.77 ALDH1A1 (0.49) DHFRKMT2AMEN1PIN1MAPT
SCHEMBL4229064 0.75 MEN1 (0.42) DHFRKMT2AMEN1MAPTALDH1A1
SCHEMBL456768 0.73 ALDH1A1 (0.44) PDE7ADHFRKMT2AMEN1MAPT
SCHEMBL31570099 0.72 MAPT (0.58) PDE7AKMT2AMEN1MAPTALDH1A1
SCHEMBL720554 0.72 MAPT (0.58) PDE7AKMT2AMEN1MAPTALDH1A1
SCHEMBL1897629 0.72 CRHBP (0.58) DHFRKMT2AMEN1MAPTALDH1A1
SCHEMBL9251355 0.72 TSHR (0.58) PDE7AKMT2AMEN1PIN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF BIOLEXIS THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
EP-2888005-B1 NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES MERCK SHARP & DOHME (US) 2019-04-03 — — EP disclosed
US-9290517-B2 Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives MERCK SHARP & DOHME CORP. (US) 2016-03-22 — — US disclosed
US-20150284411-A1 NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES MERCK SHARP & DOHME LLC 2015-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF PRKAB2, PRKAB1, PRKAR2B PDE7A 215/4885DHFR 4719/4885KMT2A 2539/4885
US-20150284411-A1 NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES PRKAG2, PRKAB2, PRKAG1 PDE7A 189/4885DHFR 398/4885KMT2A 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback